Neurogen/Pfizer NGD 91-3
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Phase II study of the anti-anxiety agent has begun. The trial is expected to enroll 280 subjects with generalized anxiety disorder. Subjects will be randomized into groups receiving a six-week dosing regimen of placebo, Pharmacia's Xanax (alprazolam) or one of two doses of NGD 91-3. Neurogen characterizes the agent as a next-generation anti-anxiety drug, designed to be fast acting without causing the sedation, memory impairment, addiction or potentiation of effects of alcohol associated with conventional anti-anxiety medication